Status:
COMPLETED
Long-term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Mth Schedule in Healthy Adults
Lead Sponsor:
GlaxoSmithKline
Conditions:
Hepatitis B
Hepatitis A
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The aim of this study is to evaluate the long-term persistence of hepatitis A and B antibodies at Years 11, 12, 13, 14 and 15 after subjects received their first dose of a 3 dose primary vaccination s...
Detailed Description
This is a long-term follow-up study at Years 11, 12, 13, 14 and 15 after primary vaccination with GSK Biologicals' hepatitis A/hepatitis B vaccine (three-dose schedule with 3 different lots). To evalu...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Subjects who had consented to participate in the long-term follow-up studies at the previous long-term blood sampling time points
- Written informed consent will have been obtained from each subject. before the blood sampling visit of each year.
Exclusion
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 20 2004
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00289770
Start Date
November 1 2004
End Date
December 20 2004
Last Update
August 17 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Wilrijk, Belgium, 2610